Crinetics Pharmaceuticals (CRNX) Operating Expenses (2017 - 2026)

Crinetics Pharmaceuticals has reported Operating Expenses for 10 years, with the latest figure at $151.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 35.2% year-over-year to $151.1 million; the trailing twelve-month figure through Mar 2026 stood at $563.8 million (up 49.36% YoY), and the FY2025 full-year result was $524.5 million, up 54.3% from the prior year.
• Operating Expenses for Q1 2026 stood at $151.1 million, up from $139.8 million in the prior quarter.
• The five-year high for Operating Expenses was $151.1 million in Q1 2026, with the low at $37.0 million in Q1 2022.
• Average Operating Expenses over 5 years is $83.2 million, with a median of $74.2 million recorded in 2024.
• Year-over-year, Operating Expenses jumped 66.68% in 2022 and gained 24.14% in 2023.
• Tracing CRNX's Operating Expenses over 5 years: stood at $48.3 million in 2022, then increased by 29.82% to $62.7 million in 2023, then soared by 51.21% to $94.7 million in 2024, then jumped by 47.58% to $139.8 million in 2025, then advanced by 8.07% to $151.1 million in 2026.
• The last three Operating Expenses figures came in at $151.1 million (Q1 2026), $139.8 million (Q4 2025), and $142.7 million (Q3 2025), per Business Quant data.

Peer Comparison